Consultancies, law firms and service providers at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
28 consultancies, law firms and service providers are at BIO-Europe 2026 — 30 presentations on the program. Most represented: Ropes & Gray (3 on the program), Graythan Regulatory Services (2 on the program), Informa (2 on the program). 18 of them have their own page in this guide. As of Sep 29, 2026.
Track
Top represented
Showing 1–16 of 28 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Ropes & Gray Boston, MA | ◆Gold Sponsor |
International law firm advising life sciences companies and investors on transactions, financing and intellectual property. | Panel Tue Nov 10 16:00–16:45 Capital, Creativity, and Optionality: The New Anatomy of Life Sciences Transactions How biotechs raise money by selling rights to future drug sales, spinning off new companies, or going public by merging with a listed one. Panel Tue Nov 10 10:45–11:15 From Partnering Pioneer to Global Biotech Leader: The Next Chapter for European Innovation How Genmab grew from licensing its discoveries to others into a global company selling its own drugs, and what European biotechs can learn. |
Regulatory consultancy advising drug developers on regulatory and commercialization pathways, including gene therapy applications. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy Panel Tue Nov 10 13:00–13:55 Unlocking APACs Clinical Trials Potential: Navigating Regulatory Pathways, Bridging Strategies and Market Access Across the Region How to run clinical trials and win approval in Japan, Korea, Taiwan and Southeast Asia, and when studies in local patients pay off. |
Informa London, United Kingdom | |
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy. | Keynote Mon Nov 9 10:45–11:00 Panel Tue Nov 10 09:00–09:45 Networks or neurons: What’s next in CNS dealmaking? What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop. Panel Wed Nov 11 14:00–14:45 BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers. |
59 North Communications Stockholm, Sweden | |
Communications agency providing branding, PR and digital marketing for life science, biotech and pharmaceutical companies. | Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. Panel Wed Nov 11 13:00–13:45 AI-Powered Ecosystems: Transforming Drug Discovery Through Digital Collaboration How drug, biotech and tech companies can build AI partnerships, and why AI finds easier wins in early discovery than in later clinical stages. |
Strategic Transactions Advisory Binningen, Switzerland | |
Boutique advisory supporting biotech and pharma companies on business development, licensing, M&A and alliance management. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy |
Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy | |
Consultancy advising pharma, medtech and digital health companies on China-Europe policy, regulation, market access and expansion. | Talk Tue Nov 10 09:30–09:45 Before the Deal: What Western Buyers Must Resolve About China-Origin Evidence and Policy Risk What Western buyers should check before buying rights to a China-developed drug, from whether its trial data satisfy European regulators to political risk. Panel Tue Nov 10 09:45–10:45 China’s Clinical Revolution: From Regional Player to Global Innovation Engine Why global drug companies license more drugs from Chinese biotechs, and how China's fast trials and changing rules can speed worldwide development. |
Venture Valuation Zurich, Switzerland | |
Values life science companies and assets and runs the Biotechgate business development database. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy |
◇Silver Sponsor | |
Life sciences consultancy advising biopharma companies on commercial strategy, market access and product launches. | Talk Mon Nov 9 09:00–10:00 Build, Buy, or Partner? Choosing Your Market Entry Strategy How drug companies choose between licensing a new product to a regional partner, selling it themselves, or both, with lessons from each path. Business of Biotech |
◆Platinum Sponsor | |
Cross-border life sciences platform helping biotech and medtech companies with market access, partnerships, investment and transactions between China and global markets. | Panel Wed Nov 11 09:00–09:45 How is the APAC region reshaping global biopharma? How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner. |
Australian not-for-profit organization providing human research ethics committee review for clinical trials and other health research. | Panel Wed Nov 11 09:55–10:25 What Starts Down Under Doesn’t Stay Down Under: Australian Clinical Data as a Global Launchpad How companies use clinical data gathered in Australia to move into multinational trials, raise investment and launch products worldwide. |
B BioXconomy | |
News outlet covering biopharma partnering, investment and business development. | Panel Wed Nov 11 13:00–13:45 Funding Outside the Box: Alternative Financing Strategies for Startups Ways biotech startups can raise money besides venture investors, such as loans or selling a share of future sales, and when each fits. |
Life sciences consultancy advising on regulatory strategy, new approach methodologies and advanced therapy medicinal products. | Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Handelsblatt Düsseldorf, Germany | |
German business and financial daily newspaper. | Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. Business of BiotechBiomanufacturing Strategy |
IGES Institut Berlin, Germany | |
Independent research and consulting institute for health care, covering health policy, health technology assessment and market access. | Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. |
Media and market-intelligence platform covering the science, business and investment of longevity. | Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Instantly find 20 buyers from consultancies, law firms and service providers
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction